SG Americas Securities LLC lifted its position in shares of ViewRay, Inc. (NASDAQ:VRAY – Get Rating) by 104.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,550 shares of the company’s stock after buying an additional 20,745 shares during the period. SG Americas Securities LLC’s holdings in ViewRay were worth $107,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Baird Financial Group Inc. acquired a new position in shares of ViewRay during the first quarter worth about $42,000. Jupiter Asset Management Ltd. acquired a new position in shares of ViewRay during the first quarter worth about $48,000. Rovin Capital UT ADV acquired a new position in shares of ViewRay during the second quarter worth about $53,000. MQS Management LLC acquired a new position in shares of ViewRay during the first quarter worth about $55,000. Finally, Lazard Asset Management LLC acquired a new position in ViewRay during the first quarter valued at approximately $58,000. 86.28% of the stock is owned by institutional investors and hedge funds.
ViewRay Price Performance
Shares of NASDAQ VRAY opened at $4.51 on Wednesday. The business’s 50 day moving average is $3.96 and its 200-day moving average is $3.36. ViewRay, Inc. has a 1-year low of $2.39 and a 1-year high of $6.28. The company has a current ratio of 2.67, a quick ratio of 2.30 and a debt-to-equity ratio of 0.56. The firm has a market cap of $818.19 million, a P/E ratio of -7.64 and a beta of 1.01.
Analyst Ratings Changes
Several research analysts recently commented on the company. StockNews.com assumed coverage on ViewRay in a research report on Wednesday, October 12th. They set a “sell” rating for the company. Piper Sandler increased their price target on ViewRay from $6.00 to $6.50 and gave the company an “overweight” rating in a research report on Wednesday, November 2nd. Morgan Stanley increased their price target on ViewRay from $4.50 to $5.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 2nd. Finally, BTIG Research reduced their price target on ViewRay to $7.00 in a research report on Thursday, October 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, ViewRay presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.
ViewRay, Inc designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns.
- Get a free copy of the StockNews.com research report on ViewRay (VRAY)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for ViewRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay and related companies with MarketBeat.com's FREE daily email newsletter.